We investigated the initial and midterm outcomes of Zilver PTX, which was approved in Japan for the first time. Patient population was the all-comer (71 patients, 81 limbs), which included 54.3% on hemodialysis, 58% of severe calcification, 61.7% of TASC D lesions and average lesion length was 204.7 ± 97.7 mm. MALE free ratios revealed 85.1% at 6 months and 70.1% at 1 year. Considering the study population which involved more than 50% of TASC D and hemodialysis patients, the initial and midterm clinical outcomes of Zilver PTX were feasible enough.
View full abstract